Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study

Abstract : AbstractBackgroundAffective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s disease (AD). The prevalence of underlying AD lesions in psychiatric diseases is unknown, and it would be helpful to determine them in patients. AD cerebrospinal fluid (CSF) biomarkers (amyloid β, tau and phosphorylated tau) have high diagnostic accuracy, both for AD with dementia and to predict incipient AD (mild cognitive impairment due to AD), and they are sometimes used to discriminate psychiatric diseases from AD. Our objective in the present study was to evaluate the clinical utility of CSF biomarkers in a group of patients with psychiatric disease as the main diagnosis.MethodsIn a multicentre prospective study, clinicians filled out an anonymous questionnaire about all of their patients who had undergone CSF biomarker evaluation. Before and after CSF biomarker results were obtained, clinicians provided a diagnosis with their level of confidence and information about the treatment. We included patients with a psychiatric disorder as the initial diagnosis. In a second part of the study conducted retrospectively in a followed subgroup, clinicians detailed the psychiatric history and we classified patients into three categories: (1) psychiatric symptoms associated with AD, (2) dual diagnosis and (3) cognitive decline not linked to a neurodegenerative disorder.ResultsOf 957 patients, 69 had an initial diagnosis of a psychiatric disorder. Among these 69 patients, 14 (20.2 %) had a CSF AD profile, 5 (7.2 %) presented with an intermediate CSF profile and 50 (72.4 %) had a non-AD CSF profile. Ultimately, 13 (18.8 %) patients were diagnosed with AD. We show that in the AD group psychiatric symptoms occurred later and the delay between the first psychiatric symptoms and the cognitive decline was shorter.ConclusionsThis study revealed that about 20 % of patients with a primary psychiatric disorder diagnosis before undergoing a CSF exploration for cognitive disorder displayed a CSF biomarker AD profile. In memory clinics, it seems important to consider AD as a possible diagnosis before finalizing a diagnosis of a psychiatric disorder.
Type de document :
Article dans une revue
Alzheimer's Research and Therapy, BioMed Central, 2016, 8 (1), pp.27. 〈10.1186/s13195-016-0192-z〉
Liste complète des métadonnées

Littérature citée [42 références]  Voir  Masquer  Télécharger

Contributeur : Bmc Bmc <>
Soumis le : mercredi 29 juin 2016 - 18:03:07
Dernière modification le : jeudi 15 mars 2018 - 10:02:06


Fichiers éditeurs autorisés sur une archive ouverte



Claire Paquet, Eloi Magnin, David Wallon, Anne-Cécile Troussière, Julien Dumurgier, et al.. Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, BioMed Central, 2016, 8 (1), pp.27. 〈10.1186/s13195-016-0192-z〉. 〈inserm-01339482〉



Consultations de la notice


Téléchargements de fichiers